MorphoSys AG has raised its financial guidance for 2018 following a new cash-generating agreement with Novartis which gives the Swiss company exclusive rights to a monoclonal antibody for atopic dermatitis that MorphoSys is developing jointly with Galapagos NV. The antibody, MOR106, targets interleukin-17C, a cytokine that plays an important role in inflammatory skin disorders.
